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Research
Ambient air pollution has been associated
with cardiovascular mortality (Forastiere et al.
2005; Peters et al. 2000; Schwartz and
Dockery 1992) and hospital admissions for
various cardiovascular diseases (Burnett et al.
1997; Schwartz 1999). Also, an elevated risk
for acute myocardial infarction (MI) (Lanki
et al. 2006; Peters et al. 2001a) and cardio-
respiratory symptoms (de Hartog et al. 2003)
has been reported in relation to air pollution.
Some studies have suggested that patients
with preexisting coronary heart disease
(CHD) (Goldberger et al. 2001) might be a
particularly susceptible population.
The exact mechanisms linking the inhala-
tion of ambient air particles to an acute exac-
erbation of cardiovascular disease are not
completely understood (Brook et al. 2004).
Alveolar inflammation induced by particles
may either directly or via oxidative stress lead
to systemic inﬂammation with increased lev-
els of blood coagulability, progression of
atherosclerosis, and destabilization or even
rupture of vulnerable plaques, resulting in
acute ischemic events (Brook et al. 2004;
Seaton et al. 1995). 
So far, studies using repeated measures to
assess the association between ambient air
particles and inﬂammatory markers have had
controversial results. In addition, they have
been conducted only on a small scale, with
samples sizes ranging from 9 to 112 (Riediker
et al. 2004; Ruckerl et al. 2006; Seaton et al.
1999). In larger studies, however, associations
have been based on single blood measure-
ments (Zeka et al. 2006), and the examined
populations have encompassed healthy and
diseased subjects, covering a variety of dis-
eases. All these differences might explain the
conﬂicting results. 
For interleukin 6 (IL-6), hypothesized to
play a central role in the triggering of the
inflammatory process (Woods et al. 2000),
associations with high levels of particulate
matter (PM) < 10 μm in aerodynamic diameter
(PM10) have been shown (van Eeden et al.
2001), although a study in elderly subjects in
the United Kingdom (Seaton et al. 1999) did
not reveal signiﬁcant associations with ambi-
ent PM10. The present study was designed to
address the responses of IL-6, ﬁbrinogen, and
C-reactive protein (CRP) to elevated air pollu-
tion levels in a large cohort of MI survivors
across Europe. We were particularly interested
in MI survivors because they are especially
prone to a progression of atherosclerosis and
adverse cardiovascular events. 
Materials and Methods
Study population. A prospective longitudinal
study of post-MI patients was performed in
six European cities—Athens (Greece),
Augsburg [Germany, KORA (Cooperative
Health Research in the Augsburg Region)
(Lowel et al. 2005)], Barcelona (Spain),
Helsinki (Finland), Rome (Italy), and
Stockholm (Sweden)—chosen to include a
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BACKGROUND: Numerous studies have found that ambient air pollution has been associated with
cardiovascular disease exacerbation. 
OBJECTIVES: Given previous ﬁndings, we hypothesized that particulate air pollution might induce
systemic inﬂammation in myocardial infarction (MI) survivors, contributing to an increased vulner-
ability to elevated concentrations of ambient particles. 
METHODS: A prospective longitudinal study of 1,003 MI survivors was performed in six European
cities between May 2003 and July 2004. We compared repeated measurements of interleukin 6
(IL-6), ﬁbrinogen, and C-reactive protein (CRP) with concurrent levels of air pollution. We col-
lected hourly data on particle number concentrations (PNC), mass concentrations of particulate
matter (PM) < 10 µm (PM10) and < 2.5 µm (PM2.5), gaseous pollutants, and meteorologic data at
central monitoring sites in each city. City-specific confounder models were built for each blood
marker separately, adjusting for meteorology and time-varying and time-invariant covariates. Data
were analyzed with mixed-effects models. 
RESULTS: Pooled results show an increase in IL-6 when concentrations of PNC were elevated
12–17 hr before blood withdrawal [percent change of geometric mean, 2.7; 95% conﬁdence inter-
val (CI), 1.0–4.6]. Five day cumulative exposure to PM10 was associated with increased ﬁbrinogen
concentrations (percent change of arithmetic mean, 0.6; 95% CI, 0.1–1.1). Results remained sta-
ble for smokers, diabetics, and patients with heart failure. No consistent associations were found
for CRP.
CONCLUSIONS: Results indicate an immediate response to PNC on the IL-6 level, possibly leading
to the production of acute-phase proteins, as seen in increased ﬁbrinogen levels. This might provide
a link between air pollution and adverse cardiac events.
KEY WORDS: air pollution, C-reactive protein, CRP, epidemiology, ﬁbrinogen, IL-6, inﬂammation,
myocardial infarction, ultrafine particles. Environ Health Perspect 115:1072–1080 (2007).
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lution characteristics [see Appendix 1 for par-
ticipants; see Supplemental Material (http://
www.ehponline.org/docs/2007/10021/
suppl.pdf) for data]. The study design is
described in detail elsewhere (Peters et al.,
in press). In brief, we recruited patients
35–80 years of age who had experienced an
MI between 4 months and 6 years before the
start of the study. Patients with MI or inter-
ventional procedures < 3 months before the
beginning of the study or with chronic recur-
ring inflammatory diseases such as Crohn’s
disease were not included. 
Preferably, current nonsmokers were
recruited. All partners approved the study pro-
tocol at their local human subjects commit-
tees, and written informed consent was
obtained from all patients. All methods used
in the study centers were conducted according
to common standard operating procedures. 
Clinical measurements. Patients were
invited to participate in six to eight clinical
visits between May 2003 and July 2004. The
visits were scheduled every 4–6 weeks on the
same weekday and at the same time of the
day to minimize the impact of weekly and
circadian variation. At the first visit, a base-
line questionnaire was administered regard-
ing health status, medication intake, and
smoking history. Blood pressure and body
mass index (BMI) were measured and a
blood serum sample was drawn to assess
baseline serum lipids, glycosylized hemo-
globin (HbA1c; an indicator of diabetic sta-
tus) and N-terminal proB-type natriuretic
peptide (NT-proBNP; an indicator for left
ventricular dysfunction). 
At each clinical visit a 7-day recall on medi-
cation intake was obtained. Venous ethylene-
diamine tetraacetic acid (EDTA)–plasma
samples were collected for the determination of
the inflammatory markers. Samples were
cooled and stored at 4°C until further process-
ing within a maximum of 4 hr. The EDTA-
blood was centrifuged at 4°C in a precooled
centrifuge for 20 min at 2,500 × g. Plasma
aliquots were shipped on dry ice to the central
laboratory in Ulm, Germany, and were stored
at –80°C until analysis. Blood samples were
analyzed by means of a commercial enzyme-
linked immunosorbent assay (ELISA) for IL-6
(quantitative high sensitive IL-6 immunoassay;
RD Systems GmbH, Wiesbaden, Germany)
and immunonephelometry for ﬁbrinogen and
high-sensitivity CRP (Dade Behring Marburg
GmbH, Marburg, Germany). Because CRP
and ﬁbrinogen concentrations were measured
by a fully automated assay, only single meas-
urements were available, except for results
above and below the detection limit, which
were double-checked. Within- and between-
patient variability for a number of blood sam-
ples that were tested as quality assurance
measures are described elsewhere (Peters
et al., in press).
Air pollution and meteorologic data. Air
pollution data from fixed monitoring sites
representing urban background concentra-
tions were collected for each city according to
standard procedures already employed in sev-
eral European studies of air pollution (Aalto
et al. 2005; Katsouyanni et al. 1996). We
obtained hourly means of particles [black
smoke (BS), black carbon (BC), mass concen-
tration of PM10, and mass concentration of
particles < 2.5 μm in diameter (PM2.5)],
gaseous air pollutants (carbon monoxide, sul-
fur dioxide, ozone, nitric oxide, nitrogen
dioxide) and meteorologic variables (air tem-
perature, relative humidity, barometric pres-
sure, dew point temperature) through
city-specific air monitoring networks and
meteorologic services. If data were recorded
locally at smaller units, at least 50% of the
data for 1 hr needed to be present for the
hourly value to be considered useable. For
valid 8- or 24-hr mean values, at least 75% of
the observations needed to be present. Particle
number concentration (PNC) measurements
as indicator for ultrafine particles were per-
formed using condensation particle counters
(CPC; 3022A; TSI, Shoreview, MN, USA) in
all centers.
Missing data on the aggregate level
were replaced using a formula adapted from
the APHEA (Air Pollution and Health—A
European Approach) method (Katsouyanni
et al. 1996) [see Supplemental Material
(http://www.ehponline.org/docs/2007/
10021/suppl.pdf)]. We calculated apparent
temperature by using the formula of
Steadman (1984) and Kalkstein and Valimont
(1986).
We used moving averages of ambient
concentrations of air pollutants and mete-
orogic variables to characterize the exposures
by calculating the individual 24-hr average
exposure for each person immediately pre-
ceding the clinical visit (lag 0) up to 4 days
(lag 1–lag 4). In addition, we calculated the
mean of lags 0–4 for the air pollution data
and the mean of lags 0 and 1, the mean of
lags 2 and 3, the mean of lags 0–3, and the
mean of lags 0–4 for the meteorologic
variables, if at least half of the relevant lags
were available.
Statistical analyses. Analytical strategy.
Given previous ﬁndings, we hypothesized that
particulate air pollution induces systemic
inflammation. Specifically, we assumed that
IL-6 would increase in association with
increased levels of ambient particle concentra-
tions of the preceding or same day, because
immediate effects on IL-6 have been shown
before (van Eeden et al. 2001), and the
cytokine has a very short half life (2–6 hr)
(Riches et al. 1992).
We also hypothesized that an acute-phase
response involving de novo synthesis of pro-
teins in the liver would require an induction
time of 1–2 days. This would translate to an
increase in ﬁbrinogen concentrations with ele-
vated particle concentrations of the previous
5 days [half-life 2–3 days (Thomas 1998)]
and an increase in CRP in association with
ambient particle concentrations 2–3 days
before blood withdrawal [half-life 19 hr
(Koenig et al. 2003)]. Similar results have
been shown in previous studies (Ruckerl et al.
2006; Seaton et al. 1999).
Statistical model. We analyzed data using
mixed-effects models with random patient
effects accounting for repeated measures.
Because the half-lives of the markers were
much shorter than the intervals between vis-
its, we assumed a compound symmetry struc-
ture for the covariance matrix to model the
correlation between repeated measures in each
patient. Penalized splines (P-splines) in the
additive mixed-model framework were used
to allow for nonparametric exposure–response
functions (Greven et al. 2006). IL-6 and CRP
needed to be log-transformed to fulfill the
model assumption of residual normality.
City-speciﬁc confounder models without
air pollutants were built for each blood marker
separately. In addition to potential time-vary-
ing confounders, we included time-invariant
patient characteristics associated with the
mean levels of inﬂammatory markers to per-
mit the assumption of a normally distributed
random patient intercept.
In a ﬁrst step, time-invariant factors were
selected for all cities combined. In the second
step, for each city a more parsimonious
model was selected out of the formerly cho-
sen variables [see Supplemental Material,
Table 1 (http://www.ehponline.org/docs/
2007/10021/suppl.pdf)]. With this strategy,
we adjusted for variables that influenced the
mean levels of the respective blood markers
in the single cities, such as age, sex, and BMI.
These variables varied among the cities, pos-
sibly reflecting underlying differences in the
populations across Europe as well as chance
influences. To ensure sufficient adjustment
for season and meteorology, long-term time
trend and apparent temperature were forced
into all models. Additionally, relative humid-
ity, time of day, and day of the week were
included if this adjustment improved the
model ﬁt. We considered lag 0, the mean of
lags 0 and 1, the mean of lags 2 and 3, and
the mean of lag 0–3 for the weather variables;
for fibrinogen, we additionally assessed the
mean of lags 0–4. P-splines were used to
model continuous covariables and were com-
pared with linear terms and polynomials of
degrees 2 and 3. All decisions on goodness-
of-ﬁt were based on Akaike’s Information Cri-
terion (AIC) (Akaike 1973). Only after this
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the inﬂammatory markers in association with
air pollution. Single air pollutants were
added and effects estimated linearly. After the
city-speciﬁc data analyses, we assessed hetero-
geneity between centers (Normand 1999).
We combined city-specific effect estimates
using meta-analysis methodology (Van
Houwelingen et al. 2002). Additionally, we
checked whether active smoking, levels of NT-
proBNP > 80 pg/mL (de Lemos et al. 2003),
and HbA1c > 6.5%, respectively, modiﬁed the
effects of air pollution on blood parameters.
Data were analyzed using the statistical
package SAS version 9.1 (SAS Institute Inc.,
Cary, NC, USA). Effect estimates are pre-
sented as percent change of geometric mean
of the blood marker level (IL-6, CRP) and
change of the arithmetic mean level (ﬁbrino-
gen, percent of overall mean) together with
95% confidence intervals (CIs) based on an
increase in air pollution concentrations from
the first to the third quartile [interquartile
range (IQR)].
Sensitivity analyses. We performed sensi-
tivity analyses to explore the robustness of
the models by using a more parsimonious
and an extended model. Also, indicator vari-
ables for season and for potential inflamma-
tion due to diseases or surgery shortly before
the blood withdrawal were added to the
model.
Results
Study population. Baseline characteristics of
the study population are given in Table 1. In
total, 1,003 MI survivors who had at least two
valid repeated blood samples were taken into
the analyses. These were 84% of the targeted
1,200 patients. 
Blood parameters. Of 6,068 collected
blood samples, 255 had to be excluded due to
acute infections or surgical procedures 3 days
before the clinic visit, because they could have
severely altered concentrations of inﬂammatory
Rückerl et al.
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Table 1. Baseline characteristics of 1,003 MI survivors from six European cities.
Characteristic Helsinki (n = 195) Stockholm (n = 197) Augsburg (n = 200) Rome (n = 134) Barcelona (n = 169) Athens (n = 108) p-Value
Percent male 68.7 70.6 82.0 86.6 83.4 87.0 < 0.0001*
Age [mean years(range)] 64.6 (45–78) 64.0 (38–76) 61.9 (39–76) 62.7 (39–79) 62.1 (37–81) 54.7 (38–75) < 0.0001**
BMI [mean (range)] 28.6 (19.1–48.9) 27.6 (17.5–43.2) 28.7 (19.1–48.4) 27.7 (19.0–39.4) 28.8 (19.3–43.5) 28.8 (20.8–46.3) 0.0039**
First MI (%) 81.5 85.8 87.5 87.3 86.4 80.6 0.37*
Self-reported history (%)a
Angina pectoris 39.0 47.7 21.0 27.6 29.6 41.7 < 0.0001*
Arrhythmia 31.3 20.8 24.0 23.1 13.0 21.3 0.0029*
Congestive heart failure 14.9 16.2 13.0 6.0 1.8 5.6 < 0.0001*
Hypertension 51.3 49.7 51.0 55.2 46.2 54.6 0.73*
Diabetes 21.0 18.3 17.5 17.2 23.7 21.3 0.63*
Chronic renal disease 3.6 2.0 5.0 5.2 9.5 1.9 0.019#
Asthma 5.1 5.6 4.5 6.7 4.7 0.0 0.0946#
Any respiratory disease 7.2 6.6 10.5 22.4 13.6 6.5 < 0.0001*
Indication of COPDb 29.2 30.6 20.5 15.7 27.8 13.9 0.007*
Total cholesterol (mg/dL)c (range) 182.2 (91.1–291.9) 173.4 (96.7–324.7) 181.0 (107.0–316.0) 190.6 (120.0–321.0) 193.2 (119.0–390.0) 195.4 (92.0–293.0) < 0.0001**
HDL cholesterol (mg/dL)c (range) 54.0 (22.0–119.3) 53.7 (30.9–116.0) 47.9 (24.0–98.0) 43.7 (25.0–87.0) 52.7 (28.0–105.0) 46.1 (24.0–87.0) < 0.0001**
HbA1c [% (range)]c 5.9 (4.7–9.2) 5.0 (3.8–9.9) 5.6 (4.7–9.8) 5.4 (2.8–8.7) 5.1 (3.8–9.8) 5.8 (3.7–10.5) < 0.0001##
Statins (%) 83 88 89 79 85 73 0.0001*
Lipid-lowering medication (%) 85 89 90 83 86 74 0.0039*
Antithrombotic medication (%) 97 97 99 95 98 93 0.058†
No. of blood samples 1,155 1,168 1,144 741 1,119 486d
IL-6 [mean (pg/mL)] 3.16 2.67 2.60 3.18 3.58 3.19
GM(range)e 2.46 (0.92–19.7) 2.02 (0.48–24.4) 2.16 (0.61–11.8) 2.32 (0.95–61.4) 2.85 (0.76–28.51) 2.52 (0.84–22.40)
Fibrinogen [mean (g/L)] 3.76 3.53 3.34 3.24 3.99 —
GM (range)e 3.69 (2.68–5.63) 3.44 (2.24–6.11) 3.27 (2.00–6.87) 3.14 (1.94–5.18) 3.91 (2.62–6.02) —
CRP [mean (mg/L)]f 1.98 2.86 2.26 2.56 3.52 2.52
GM (range)f 1.18 (0.16–12.15) 1.42 (0.16–37.44) 1.18 (0.16–24.65) 1.40 (0.16–15.33) 2.03 (0.33–30.16) 1.32 (0.23–24.25)
COPD, chronic obstructive pulmonary disease.
aEver physician diagnosed. bEvaluated using a questionnaire on symptoms.cBlood biomarkers determined at local laboratories. dFor ﬁbrinogen N = 0. eGeometric mean of patients’ geo-
metric mean of repeated measurements. fValues of CRP < 0.16 could not be measured and were set to 0.16. p-Values determined with*chi-square test, **ANOVA, #Fisher´s exact test,
##Median-test, †Kruskal-Wallis test.
Table 2. Twenty-four-hour average concentrations of the ambient air pollution concentrations and meteorologic parameters from six European cities during the
AIRGENE study period.a
Helsinki Stockholm Augsburg Rome Barcelona Athens
5 Sep 03–2 Jun 04 30 Aug 03–24 Jun 04 14 May 03–24 Feb 04 20 Sep 03–15 Jul 04 30 Aug 03–16 Jun 04 8 Sep 03–30 Jul 04
Pollutant Mean (95th) Mean (95th) Mean (95th) Mean (95th) Mean (95th) Mean (95th)
PNC (1/cm3) 8,534 (15,077) 9,748 (17,578) 11,876b (25,135) 35,450b (69,226) 18,133b (36,526) 20,589b (47,573)
PM2.5 (µg/m3) 8.2 (19.4) 8.8 (19.1) 17.4 (29.3) 24.5b (54.1) 24.2b (62.7) 23.0b (46.0)
PM10 (µg/m3) 17.1 (36.1) 17.8 (40.3) 33.1 (56.6) 42.1 (76.0) 40.7b (88.7) 38.5 (64.6)
CO (mg/m3) 0.31 (0.46) 0.29 (0.43) 0.58 (1.00) 1.40 (2.47) 0.59 (0.92) 1.48 (3.23)
NO2 (µg/m3) 28.6 (49.8) 18.6 (32.6) 40.0 (61.2) 67.0 (90.8) 50.5 (79.6) 50.1 (73.0)
NO (µg/m3) 12.5 (40.7) 4.9 (15.5) 30.0 (80.4) 65.7 (164.0) 37.7 (88.4) 41.8 (144.6)
SO2 (µg/m3) 4.2 (10.1) 1.9 (4.9) 3.0 (5.7) 4.1 (9.2) 4.7 (9.6) 10.3 (23.2)
O3 [8-hr average ([µg/m3)] 46.8 (89.0) 60.6 (96.9) 54.4 (115.3) 45.3 (99.6) 28.2 (76.5) 59.8 (100.2)
Air temperature (°C) 3.1 (14.7) 4.7 (15.1) 10.2 (25.1) 13.4 (23.9) 15.2 (23.2) 17.6 (29.3)
Relative humidity (%) 76 (91) 82 (94) 69 (92) 80 (95) 67 (86) 67 (84)
95th, 95th percentile.
aThe study period started 5 days before the ﬁrst measurement because a priori air pollution concentrations up to 5 days before the blood withdrawals were considered. bData available
on < 95% of the days. markers. Overall, 5,813 plasma samples
remained. For Athens, ﬁbrinogen levels could
not be assessed. IL-6, fibrinogen, and CRP
showed a moderate correlation, with the
Spearman correlation coefﬁcient ranging from
0.41 to 0.51 for all single measurements and
from 0.49 to 0.55 for the mean values per
patient, with the data of all cities combined.
The single cities showed similar correlation
coefficients, Barcelona being the only excep-
tion, with a low correlation between ﬁbrinogen
and IL-6 (r = 0.22 and 0.25, respectively). 
Air pollutants. The 24-hr average concen-
trations of the pollutants and meteorologic
data are given in Table 2. PNC and PM2.5
were highest in the southern cities and lowest
in Stockholm and Helsinki, whereas Augsburg
showed intermediate levels (Figure 1).
Regression results. The pooled results for
the regression of the three blood markers are
summarized in Table 3. IL-6 showed border-
line significant increases in association with
PNC and NO2 with lag 0, one of the two
a priori speciﬁed lags (Figure 2). Because IL-6
showed positive associations for lag 0, we ana-
lyzed the 24 hr of air pollution exposure
before the blood withdrawal in more detail.
PNC results indicate a time response with a
slight increase 6–11 hr after an exposure, a
clear increase with 12–17 hr after an expo-
sure, and a drop back to the level of 0–5 hr
thereafter (Figure 3). Results for 6–11 as well
as 12–17 hr for all single cities show
clear positive associations, except for Helsinki
and Athens (6–11 hr) and Helsinki and
Stockholm (12–17 hr). 
Fibrinogen was associated with an
increase for the 5-day-average exposure of
PM10. Other pollutants also indicate an
increase for the 5-day-averages, but CIs were
wide. In addition to the effect for the cumula-
tive exposure, we found an increase for fib-
rinogen with lag 3 for PM2.5 and PM10
(Figure 3). For lag 3, results of the single
cities show clear positive associations with
PM2.5 for all cities except for Augsburg,
where no association was seen. For PM10 and
lag 3, results are heterogeneous. Except for
Air pollution and inflammation
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Figure 1. Time series of air pollution (PNC and PM2.5) and air temperature in the six European cities of the AIRGENE study.
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Helsinki Stockholm
Augsburg Rome
Barcelona Athens
PM2.5
PNCAugsburg, all cities present positive associa-
tions, with Helsinki being the highest.
Associations for PM2.5 and PM10 for the
5-day-average exposures were positive in
all cities.
Analyses of effect modiﬁcation showed that
for fibrinogen associations remained for the
5-day average exposure to PM10 for nonsmok-
ers and patients with elevated NT-proBNP
and HbA1c levels (Figure 4). Results for the
single cities revealed clear positive associations
for patients with elevated HbA1c levels in
Helsinki and Barcelona, and small positive
associations in Augsburg and Rome, whereas
no association was found for Stockholm.
Helsinki and Barcelona showed clear increases
in fibrinogen levels with increased PM10 for
patients with high NT-proBNP levels,
whereas for the other cities only small
increases were found. Active smokers were
present only in Rome and Barcelona, and
interactions with smoking thus were calcu-
lated only for these two cities. The combined
results are driven mainly by the results from
Barcelona, which indicate a strong positive
association for nonsmokers. For CRP, no
associations between ambient air pollution
and serum concentrations were observed for
either the a priori hypothesized time span or
other lags.
Sensitivity analyses. We performed sensi-
tivity analyses for all blood markers, using
selected air pollutants and the a priori speci-
ﬁed lags (Table 4). For IL-6 and PNC, addi-
tional confounders in the model led to a clear
positive result, whereas all other models,
including the chosen model, were more con-
servative. For fibrinogen, overall results
remained clearly positive and stable with
PM10. With PNC a strong yet not signiﬁcant
association was found for the model without
time-independent covariates. For CRP,
results did not change in dependence on
the model. 
Discussion
We measured IL-6, fibrinogen, and CRP,
three blood markers that indicate an inﬂam-
matory response, in MI survivors in six
European cities. Pooled results show an
increase in IL-6 when concentrations of PNC
were elevated 12–17 hr before the clinical
visit. Cumulative exposure to PM10 was
associated with an increase in ﬁbrinogen. No
Rückerl et al.
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Table 3. Effects of air pollution on blood biomarkers per increase in IQR of air pollutant (pooled effect estimates). 
IL-6 (all cities) Fibrinogen (all cities except Athens) CRP (all cities)
Pollutant, Time  before  %  change  p-Value %  change  p-Value %  change  p-Value 
IQR blood withdrawal (GM) 95% CI heterogeneity (AM) 95% CI heterogeneity (GM) 95% CI heterogeneity
PNCa
11852 Lag 0 1.88** –0.16 to 3.97 0.72 0.40 –0.40 to 1.19 0.54 1.33 –3.05 to 5.90 0.047
11852 Lag 1 –0.67 –2.56 to 1.25 0.64 0.11 –0.69 to 0.91 0.12 –1.52 –4.39 to 1.45 0.19
11852 Lag 2 –2.12** –4.03 to –0.17 0.055 0.09 –0.71 to 0.90 0.045 –1.63 –6.70 to 3.71 0.019
11003 5-day average –0.93 –3.37 to 1.56 0.084 0.50 –2.20 to 3.20 0.009 –0.08 –3.78 to 3.75 0.12
PM2.5
b
11.0 Lag 0 0.46 –0.89 to 1.83 0.26 0.05 –0.48 to 0.58 0.36 0.11 –1.95 to 2.21 0.71
11.0 Lag 1 –0.39 –1.69 to 0.93 0.70 0.17 –0.35 to 0.69 0.55 –0.06 –1.98 to 1.90 0.70
11.0 Lag 2 –0.23 –1.53 to 1.07 0.57 0.20 –0.32 to 0.71 0.26 0.11 –1.80 to 2.06 0.86
8.6 5-day average 0.05 –1.37 to 1.50 0.66 0.38 –0.21 to 0.96 0.21 –0.13 –2.15 to 1.92 0.94
PM10
c
17.4 Lag 0 –0.34 –1.66 to 0.99 0.45 0.06 –0.43 to 0.55 0.53 –0.71 –2.75 to 1.37 0.16
17.4 Lag 1 –0.69 –1.95 to 0.58 0.43 0.14 –0.35 to 0.63 0.83 –0.63 –2.61 to 1.39 0.23
17.4 Lag 2 –1.59 –3.99 to 0.88 0.0030 0.24 –0.24 to 0.72 0.25 –1.42 –4.23 to 1.47 0.086
13.5 5-day average –0.87 –2.28 to 0.55 0.15 0.60* 0.10 to 1.09 0.26 –1.35 –3.45 to 0.79 0.19
CO
0.34 Lag 0 0.57 –0.63 to 1.79 0.95 0.24 –0.45 to 0.92 0.11 –0.01 –1.72 to 1.73 0.18
0.34 Lag 1 0.44 –0.79 to 1.68 0.72 0.32 –0.35 to 1.00 0.38 –1.51 –3.30 to 0.32 0.19
0.34 Lag 2 –2.36 –4.82 to 0.17 0.0054 –0.44 –1.11 to 0.23 0.078 –2.35 –6.84 to 2.36 0.0025
0.31 5-day average –0.28 –2.53 to 2.02 0.067 0.12 –0.81 to 1.05 0.062 –0.85 –5.37 to 3.90 0.051
NO2
15.9 Lag 0 1.31** –0.24 to 2.89 0.97 0.05 –0.50 to 0.60 0.84 0.41 –1.93 to 2.81 0.68
15.9 Lag 1 0.93 –0.55 to 2.43 0.78 0.04 –0.49 to 0.57 0.64 1.15 –1.18 to 3.54 0.86
15.9 Lag 2 –1.38 –4.35 to 1.68 0.00024 0.05 –0.71 to 0.80 0.056 –0.28 –4.05 to 3.63 0.0081
10.1 5-day average –0.19 –3.08 to 2.78 0.0014 0.24 –0.45 to 0.93 0.057 1.40 –0.92 to 3.79 0.19
Abbreviations: AM, arithmetic mean; GM, geometric mean. A priori speciﬁed lags: IL-6: lag 0 and lag 1; ﬁbrinogen: 5-day average; CRP: lag 2. 
aIQR (24-hr, 5-day average), 11852.39408, 11002.9686 n/cm3. bIQR (24-hr, 5-day average), 10.99720847, 8.59343322 µg/m3. cIQR (24-hr, 5-day average), 17.36794382, 13.5380001 µg/m3. 
*p < 0.05; **p < 0.1. 
Figure 2. Association between PNC and PM10 and blood markers for the single cities for the a priori speciﬁed lags. (A) IL-6. (B) Fibrinogen. (C) CRP. Abbreviations:
AM, arithmetic mean; GM, geometric mean.
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for CRP.
Air pollution seems to affect susceptible
subgroups (Goldberg et al. 2001, 2006;
Katsouyanni et al. 2001; Pope et al. 2002).
We therefore examined MI survivors, a sub-
group with an increased risk for readmission
to the hospital (von Klot et al. 2005), in six
European cities, covering a wide range of
gaseous and particulate air pollutants. There
is a strong link between inflammation and
CHD because factors involved in inflamma-
tion and infection seem to play a pro-athero-
genic role, and inflammation has been
identified as a potent risk factor for acute
ischemic syndromes (Ross 1999). Other risk
factors such as cigarette smoking (Danesh
et al. 1999: Fröhlich et al. 2003), diabetes
(Thorand et al. 2007), or high BMI (Danesh
et al. 1999: Thorand et al. 2006) have also
been found to be associated with low-grade
systemic inflammation, providing a further
link between inflammation and acute
coronary events. 
Previous studies have shown an associa-
tion between air pollution and blood markers
of inﬂammation and coagulation. We exam-
ined IL-6 because of its role in the inﬂamma-
tory cascade (Woods et al. 2000). IL-6 is
produced by different cells in the body,
including lymphocytes, monocytes, and
endothelial cells. It is thought to play a major
role in mediating stimuli from activated
macrophages—for example, by smoking. IL-6
is the key cytokine that stimulates the synthe-
sis of all major acute phase proteins, including
CRP and fibrinogen (Woods et al. 2000).
The latter factor induces an increase in blood
viscosity and promotes thrombus formation
(Koenig 2003).
In a study in the United Kingdom (Seaton
et al. 1999), no significant associations were
seen for a 3-day cumulative exposure to ambi-
ent PM10 and IL-6 levels. At high pollution
levels, however, such as in road tunnels or dur-
ing forest ﬁres, positive associations have been
observed (Hilt et al. 2002; van Eeden et al.
2001). Our results indicate an increase in IL-6
within 12 hr after exposure, a requisite first
step in the stimulation of the de novo synthesis
of acute-phase proteins in the liver, triggered
by ambient particles. 
Fibrinogen, an acute-phase protein, also
plays a crucial role in the coagulation cascade.
Studies regarding its association with air pollu-
tion are inconclusive. It has been shown to
increase in association with high levels of ambi-
ent particles such as in an air pollution episode
(Peters et al. 1997) or in controlled human
exposure studies (Ghio et al. 2000). Also, posi-
tive associations, such as for PM10, have been
reported at levels comparable to those meas-
ured in the present study (Pekkanen et al.
2000; Schwartz 2001). However, also null
associations (Pope et al. 2004; Ruckerl et al.
2006) and even decreases in fibrinogen con-
centration in association with air pollutants
have been reported (Khandoga et al. 2004;
Seaton et al. 1999). Our study indicates an
increase in ﬁbrinogen for lag 3 and the 5-day
cumulative exposure for PM10.
CRP, a well-known biomarker of systemic
inﬂammation, has been one of the ﬁrst acute-
phase reactants to be examined in association
with air pollution in several studies. Increased
concentrations have been shown during an air
pollution episode in Germany in healthy
men, 45–64 years of age (Peters et al. 2001b)
as well as for ambient PM10 levels currently
present in Europe (Seaton et al. 1999).
Additionally, in a panel of CHD patients, an
increase in CRP above the 90th percentile
was found in association with ambient parti-
cles (Ruckerl et al. 2006). Similar analyses did
not reveal any effects in our data, which
might be attributed to differences in the two
panels. The AIRGENE panel consisted of
both males and females and was on average
slightly younger, but had more severe diseases
than the subjects studied previously. On the
other hand, the average CRP levels were
lower in the AIRGENE panel. 
Overall, these studies suggest associations
between inﬂammation and ambient air pollu-
tion concentrations, especially particles,
although the effects between studies differ for
individual data. To date, the reason for the
heterogeneity is largely unknown. Different
pollution mixtures, underlying medical con-
ditions, treatments or diets with high anti-
oxidant levels might be possible explanations. 
We observed immediate associations
between PNC and IL-6 and cumulative
effects between PM10 and ﬁbrinogen. This is
a surprising finding, which might be attrib-
uted to chance, because PM10 and PNC were
not highly correlated in most cities. It is,
however, also possible that their mode of
action is different. Ultrafine particles or
attached substances might translocate quickly
into the bloodstream (Geiser 2002) and lead
to the observed changes in IL-6 without hav-
ing a direct impact on the lung. PM10, on the
other hand, might only exert an indirect sys-
temic impact by provoking an inﬂammatory
response in the lung that eventually causes
oxidative stress, leading to the observed
delayed increase in fibrinogen. However,
these explanations are highly speculative.
Further, PNC and PM10 differ not only by
size but also by composition and redox activ-
ity (Cho et al. 2005), but the implications for
the mechanisms are difﬁcult to judge. When
the city-specific results are examined, the
immediate association between IL-6 and
PNC was strongest in Augsburg, whereas the
association between PM10 and ﬁbrinogen was
strongest in Helsinki for the 5-day-average
exposure. Because these city-speciﬁc estimates
were not heterogeneous, this may reflect the
expected variation between independent stud-
ies. It also might point to differences in mea-
surement error with respect to population
average exposures characterized by central
monitoring sites.
One possible explanation for the lack of
associations between air pollutants and CRP
in our data could be the high prevalence of
Air pollution and inflammation
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Figure 4. Effects of PM10 on ﬁbrinogen (5-day aver-
age) as modified by active smoking, levels of NT-
proBNP and HbA1c as indicators of left ventricular
dysfunction and diabetes, respectively. AM, arith-
metic mean. Error bars indicate 95% CIs. 
aActive smokers were only present in Rome and Barcelona;
interaction thus calculated only for these two cities. 
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Figure 3. Pooled effects of PNC on IL-6 (A) and of PM2.5 and PM10 (B) on fibrinogen, different lags.
Abbreviations: AM, arithmetic mean; GM, geometric mean. Error bars indicate 95% CIs.
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PM2.5 PM10lipid-lowering drugs intake, particularly
statins, which have been shown to reduce
CRP through inhibition of its hepatic synthe-
sis (Arnaud et al. 2005). Studies have shown
that long-term therapy with a statin signifi-
cantly lowers plasma levels of CRP (Ridker
et al. 2001; Sandhu et al. 2005). IL-6, which
is produced upstream to the production of
CRP in the liver, is not affected by this com-
pound. Also, ﬁbrinogen has been implicated
to be reduced by fibrates but not statins
(Rosenson et al. 2001). Because the majority
of our patients reported an intake of statins,
subgroup analyses did not seem reasonable. 
Increased concentrations of CRP are
known to predict cardiovascular events in
healthy subjects (Danesh et al. 2000). Also,
elevated levels of IL-6 have been found to be
associated with total mortality (Harris et al.
1999) and with risk of future fatal and nonfa-
tal MI (Ridker et al. 2000). Whether the
short-term increases in IL-6 and fibrinogen
observed in this study actually lead to an
increased risk for an acute coronary syndrome,
however, remains to be shown. A long-term
follow-up study examining cardiovascular end
points might help to answer the question
whether subjects with elevated levels of
inﬂammatory proteins in response to environ-
mental stimuli have an increased risk of acute
ischemic syndromes.
Strengths and limitations. The study is
based on a common protocol and standard
operating procedures applied in six European
cities. Site visits were conducted to ensure uni-
form procedures. The analyses of the inﬂam-
matory markers were done in one central
laboratory, and blinded duplicate samples
were measured for quality assurance. 
Some of the measured biomarkers (e.g.,
CRP) are affected by health-related events
such as acute infection or surgery (Thomas
Rückerl et al.
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Table 4. Sensitivity analyses: results for different models on selected outcomes.
IL-6 (lag 0) Fibrinogen (mean of 5-day average) CRP (lag 2)
Estimate Heterogeneity Estimate Heterogeneity Estimate Heterogeneity
Pollutant, model  (% change GM) 95% CI  (p-value) (% change AM) 95% CI  (p-value)  (% change GM) 95% CI  (p-value) 
PNC
Main model  1.88 –0.16 to 3.97 0.72 0.5 –2.20 to 3.20 0.009 –1.63 –6.70 to 3.71 0.02
Additional covariatesa 2.16* 0.08 to 4.29 0.85 0.26 –2.96 to 3.48 0.004 –1.64 –7.02 to 4.05 0.01
No time-independent covariates  1.16 –0.85 to 3.21 0.46 2.77 –0.15 to 5.69 0.001 –1.92 –6.93 to 3.36 0.02
Including risk of potential inﬂammation 1.91 –0.14 to 3.99 0.70 0.48 –2.37 to 3.32 0.01 –1.74 –6.78 to 3.57 0.02
4–7 days before blood withdrawal
Including seasonal interaction  1.97 –0.11 to 4.09 0.61 0.35 –0.80 to 1.51 0.02 –1.18 –6.59 to 4.55 0.01
(season = winter)
PM10
Main model –0.34 –1.66 to 0.99 0.45 0.60* 0.10 to 1.09 0.26 –1.42 –4.23 to 1.47 0.086
Additional covariatesa –0.16 –1.48 to 1.17 0.53 0.81* 0.17 to 1.45 0.19 –1.08 –3.05 to 0.92 0.11
No time-independent covariates  –0.64 –1.94 to 0.69 0.44 0.36 –0.77 to 1.48 0.02 –2.04 –5.05 to 1.07 0.04
Including risk of potential inﬂammation –0.35 –1.66 to 0.99 0.44 0.75 0.12 to 1.38 0.34 –1.43 –4.21 to 1.43 0.09
4–7 days before blood withdrawal
Including seasonal interaction  –0.15 –1.71 to 1.42 0.40 0.78 –0.02 to 1.57 0.50 –1.33 –3.61 to 1.00 0.55
(season = winter)
Estimates for CRP and IL-6 are expressed as percent change in expected geometric mean (GM); estimates for fibrinogen are expressed as absolute change in expected mean,
expressed as percent of overall arithmetic mean (AM). 
aAdditional covariates included time-independent variables present in at least two cities, hour of blood withdrawal, and relative humidity. *p < 0.05.
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2000). We therefore carefully excluded blood
samples that might have been strongly inﬂu-
enced by other sources than air pollution
before the statistical analyses. Moreover, thor-
ough confounder adjustment was done to rule
out the possibility that the detected associa-
tions resulted from meteorologic inﬂuences or
seasonal differences, and repeated measures
decreased the chance of confounding by time-
independent variables, because each person
served as his or her own control. 
Even though we included city-specific
patient characteristics to account for differ-
ences in the panels, the city-speciﬁc estimates
of the air pollution effects still varied.
However, for those results indicating an asso-
ciation between air pollution and inflamma-
tion, these variations did not exceed the
expected random variation. But it is also quite
possible that the air pollution mixture, socioe-
conomic factors, or genetic background are
responsible for these modifications. Indeed,
we did observe effect modiﬁcation for patients
with elevated HbA1c and NT-proBNP.
We observed only small changes in the
acute-phase response that are not on the scale
of a bacterial infection (Thomas 2000) or
surgery and presumably do not have any direct
clinical relevance. Other factors, such as 10
pack-years of smoking, in comparison, led to
increases of 2.7% (95% CI, 1.2–4.3) for IL-6,
1.2% (95% CI, 0.7–1.7) for ﬁbrinogen, and
5.5% (95% CI, 3.0–8.0) for CRP in our data.
A higher BMI of 5 kg/m2 was associated with
signiﬁcantly higher levels of IL-6 (16%), ﬁb-
rinogen (3.8%), and CRP (38%). Smoking
and overweight may be of concern in subpop-
ulations, whereas air pollution usually affects
whole populations and there is generally no
voluntary component to the risk. Based on a
publication by Cesari et al. (2003), we esti-
mated that the increase in IL-6 we found in
association with PNC might lead to a 0.7%
(95% CI, –0.06 to 1.5) increased risk of
CHD in elderly people without baseline car-
diovascular risk. Despite the high prevalence
of statin intake, our data still indicate an
inﬂammatory response in association with air
pollution. We therefore hypothesize that
ambient air pollution might increase plaque
vulnerability by these subclinical inﬂammatory
responses. 
Conclusion 
Our results indicate an immediate response of
IL-6 to ambient air pollution, which might
lead to the synthesis of acute-phase proteins, as
indicated by increased ﬁbrinogen levels. The
lack of detectable associations for CRP may be
attributed to a widespread intake of statins in
our population, which might suggest a protec-
tive effect against environmental, proinflam-
matory stimuli—an intriguing phenomenon
that deserves further study.
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